KARA KANE: Open Payments
NPI 1497390645 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,058 in 101 payments from 22 companies in 2025. Trend: 2023 $1,772 · 2024 $2,271 · 2025 $2,058
Food & beverage: $2,058
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $337 |
| Janssen Biotech, Inc. | 13 | $242 |
| ABBVIE INC. | 20 | $229 |
| GENZYME CORPORATION | 7 | $186 |
| Lilly USA, LLC | 3 | $160 |
| Incyte Corporation | 10 | $152 |
| UCB, Inc. | 3 | $107 |
| REVANCE THERAPEUTICS, INC. | 1 | $76 |
| E.R. Squibb & Sons, L.L.C. | 3 | $75 |
| Biofrontera Inc. | 2 | $61 |
Products named: COSENTYX, DUPIXENT, TREMFYA, OPZELURA, EBGLYSS, SKYRIZI, Bimzelx, RINVOQ.
Industry payments across CA — which companies pay providers there.
